# Shukra Pharmaceuticals share price today (Shukra Pharmaceuticals Ltd, NSE: SHUKRAPHAR)

> Shukra Pharmaceuticals share price today: ₹79.85 at the NSE close on 3 November 2026, up 94.7% in a year. Shukra Pharmaceuticals (NSE: SHUKRAPHAR) is worth ₹3,532 crore, trades at a P/E of 98.0 and has closed between ₹28.99 and ₹79.85 over the past 52 weeks. > Shukra Pharmaceuticals Ltd's earnings have grown faster than its share price. Earnings per share grew +127.3% in a year while the price moved +94.7%. SHUKRAPHAR · Pharma - Others · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from fewer quarters than usual
- Price: ₹79.85 (+94.7% in a year)
- P/E: 98.0× (higher than 84% of the last 11 years)
- Revenue (Jun 2026): ₹24.0 Cr (+380.0% on a year ago)
- Profit (Jun 2026): ₹15.0 Cr (+1,400.0% on a year ago)
- Operating margin: 90.0% (+66.0 points on a year ago)
- ROCE: 37%, FY26
- Profit that came in as cash: 12%, last 3 years

The main question: profits are rising, but only 12% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Shukra Pharmaceuticals share price today? Shukra Pharmaceuticals Ltd's share price was ₹79.85 at the close on 3 November 2026. It has been rising for 10 weeks. That is 81.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹29 and ₹80, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 14 weeks in a row. Over the last 11 years the share price moved +30,612% while the NIFTY 500 moved +251%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Shukra Pharmaceuticals this quarter? Three changes stood out: best operating margin in 15 quarters, number of shareholders up 63% in a year and closed the week at a 52-week high. 1. Best operating margin in 15 quarters Operating margin was 90% in the June 2026 quarter, against 24% a year earlier. 2. Number of shareholders up 63% in a year 35,007 shareholders in the September 2026 quarter, against 21,441 a year earlier. 3. Closed the week at a 52-week high ₹74.95 on 30 Oct 2026, the highest weekly close in a year. ## What are Shukra Pharmaceuticals' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Shukra Pharmaceuticals reported revenue of ₹24.0 crore, up 380.0% from ₹5.00 crore a year earlier, and a profit of ₹15.0 crore, up 1,400.0% from ₹1.00 crore. ### Shukra Pharmaceuticals results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹24.0 crore | ₹5.00 crore | +380.0% |
| Profit | ₹15.0 crore | ₹1.00 crore | +1,400.0% |
| Earnings per share | ₹0.34 | ₹0.02 | +1,600.0% |
| Operating margin | 90.0% | 24.0% | +66.0 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Shukra Pharmaceuticals share price history? Shukra Pharmaceuticals closed at ₹79.85 on 3 November 2026, up 94.7% from ₹41.01 a year earlier (31 October 2025) and up 31,840.0% over five years. Its highest weekly close since March 2016 was ₹79.85 on 3 November 2026. ### Shukra Pharmaceuticals share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹64.58 | +23.6% |
| 1 month ago · 1 Oct 2026 | ₹61.84 | +29.1% |
| 1 year ago · 31 Oct 2025 | ₹41.01 | +94.7% |
| 3 years ago · 3 Nov 2023 | ₹2.65 | +2,913.2% |
| 5 years ago · 3 Nov 2021 | ₹0.25 | +31,840.0% |
| 10 years ago · 4 Nov 2016 | ₹0.38 | +20,913.2% |
| Earliest weekly close in our records · 11 Mar 2016 | ₹0.26 | +30,611.5% |
| Highest weekly close since March 2016, also the 52-week high · 3 Nov 2026 | ₹79.85 | 0.0% |
| Lowest weekly close since March 2016 · 16 Jul 2020 | ₹0.13 | +61,323.1% |
| 52-week low (weekly close) · 29 May 2026 | ₹28.99 | +175.4% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (516 weekly closes from 11 March 2016 to 3 November 2026.)

## What is the latest news on Shukra Pharmaceuticals? 3 Nov 2026: Shukra Pharmaceuticals closed at ₹79.85, up 23.6% on the week and up 29.1% on the month. 21 Sep 2026: ex-date for a dividend of ₹0.01 a share. ### Earlier

- Results for April to June 2026: Revenue up 380.0% and profit up 1,400.0% on a year earlier. ## What dividend does Shukra Pharmaceuticals pay? Shukra Pharmaceuticals paid ₹0.01 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.01% at the ₹79.85 close on 3 November 2026. The last was a dividend of ₹0.01 a share, ex-date 21 September 2026. ### Shukra Pharmaceuticals dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 21 Sep 2026 | ₹0.01 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 0 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Shukra Pharmaceuticals Ltd paid out 2% of its profit as dividends in FY26, and it paid a dividend in 8 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Shukra Pharmaceuticals on? Shukra Pharmaceuticals is on 3 of our India lists: Momentum stocks, Penny stocks and Pharma stocks. - [Momentum stocks Market cap cr: 3535.5776679577934](https://www.sectoralpha.in/momentum-stocks-india)
- [Penny stocks Earnings growth, 12 months (%): 268.18](https://www.sectoralpha.in/penny-stocks-india)
- [Pharma stocks Market value (₹ crore): 3535.5776679577934](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Shukra Pharmaceuticals profitable? Shukra Pharmaceuticals Ltd earned ₹15.0 Cr of net profit in the Jun 2026 quarter, +1,400.0% on the same quarter a year earlier. Full-year FY26 profit was ₹22.0 Cr. That is 62.5% of the quarter's revenue. The same quarter a year earlier earned ₹1.0 Cr. 1 of the last 12 reported quarters were loss-making. For the full year, FY26 profit was ₹22.0 Cr (+120.0% on the year before). Why profit moved: revenue changed +380.0% on a year earlier and the margin moved +66.0 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +481.7% and revenue +145.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Shukra Pharmaceuticals make, and is it growing? Shukra Pharmaceuticals Ltd reported ₹24.0 Cr of revenue in the Jun 2026 quarter, +380.0% on the same quarter a year earlier. Over 10 years it has grown 27.6% a year on average. The last full year, FY26, came in at ₹57.0 Cr. The last four reported quarters add to ₹75.0 Cr. FY26 revenue was ₹57.0 Cr, +72.7% on the year before. Recent pace: the last four quarters grew +145.2% on average, against 27.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +114.3%, against +13.7% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +250.0%, against +39.4% a year (accelerating). ## How much of every ₹100 of sales does Shukra Pharmaceuticals keep? Shukra Pharmaceuticals Ltd's operating margin was 90.0% in the Jun 2026 quarter, 66.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between −10.0% and 51.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +65.7 percentage points on the year while gross margin changed +20.8 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Shukra Pharmaceuticals' profit turning into cash? Over the last 3 years, 12% of Shukra Pharmaceuticals Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹3.0 Cr of operating cash against ₹22.0 Cr of profit. After ₹16.0 Cr of spending on assets, free cash was −₹13.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Shukra Pharmaceuticals' cash go? Shukra Pharmaceuticals Ltd's customer, stock and supplier day counts come out in the thousands of days on sales this small (₹57.0 Cr in FY26), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹20.0 Cr on assets over the last 3 years. Averaged over those years that is 11.7% of FY26 revenue a year. Spending on assets: ₹20.0 Cr over the last 3 years, against ₹8.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹12.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Shukra Pharmaceuticals' P/E ratio, and how does it compare with its own history? Shukra Pharmaceuticals Ltd's P/E is 98.0×, near the high end of its own history: higher than 84% of past readings. Its usual P/E (the middle reading) is 42.3×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +127.3% while the price moved +94.7%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +216.9% a year; about +140.8% a year came from earnings growth and about +76.1 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 18% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Shukra Pharmaceuticals business getting better or worse? Shukra Pharmaceuticals Ltd's business is turning around. Profit growth has swung from −50.0% at its low to +250.0%, rising from a low 5 quarters ago, with ROCE rising at 37.0%. This is based on 8 quarters of 4 measures, with some gaps. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Shukra Pharmaceuticals earn on its capital? Shukra Pharmaceuticals Ltd earned a ROCE of 37% in FY26. That is up from a low of −6% in FY14. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 38.6% net margin and 0.49× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 38.6% net margin × 0.49× asset turnover × 1.30× leverage (assets divided by equity) ≈ 24.6% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 18% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Shukra Pharmaceuticals have too much debt? Shukra Pharmaceuticals Ltd had ₹5.0 Cr of borrowings against ₹90.0 Cr of equity in FY26, so its debt is 0.06× its equity. Its operating profit is 29 times its interest bill. Over 5 years borrowings went from ₹10.0 Cr to ₹5.0 Cr. Over the last 3 of those years it spent ₹20.0 Cr on assets. The spending on assets is being paid for from cash, not new debt. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 18% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Shukra Pharmaceuticals shareholding pattern? No group of Shukra Pharmaceuticals Ltd's owners changed its stake by a full percentage point over the last two years. Promoters moved +0.2 points over the same period, to 51.2%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +0.4 points over 8 quarters, to 0.4%; Promoters: +0.2 points over 8 quarters, to 51.2%; Domestic institutions: +0.1 points over 8 quarters, to 0.2%. ## How far is Shukra Pharmaceuticals from balance-sheet trouble? For Shukra Pharmaceuticals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Shukra Pharmaceuticals rank in its industry? 69.7 out of 100, rank 2 of 10 in Pharma - Others, with 56% of the evidence available. Shukra Pharmaceuticals Ltd scores 69.7 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 2. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 28.5 + 19.4 + 9.3 + 12.5 = 69.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Shukra Pharmaceuticals compared with? Shukra Pharmaceuticals ranks 2 of 10 Pharma - Others companies on the 4-Factor Sector Score, with 69.7 out of 100. 1. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) SYNCOMF · breaking out · Most evidence points up · 89% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 0.4% · Profit 48.3% · Operating margin change 7 points · 88% evidence Capital efficiency 17.2/25 · ROCE 24.7% · Operating margin 21% · 100% evidence Valuation 15.1/20 · P/E 21.2× · PEG 0.79 · 65% evidence Relative strength 17.8/20 · Lead over its industry -0.2% · Lead over NIFTY 500 32.3% · 1 year 16.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.4 + 17.2 + 15.1 + 17.8 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. Shukra Pharmaceuticals Ltd this page SHUKRAPHAR · breaking out · Too little evidence to rank firmly · 56% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/35 · Revenue 100% · Profit 100% · Operating margin change 66 points · 83% evidence Capital efficiency 19.4/25 · ROCE 37% · Operating margin 90% · 76% evidence Valuation 9.3/20 · P/E 91.9× · PEG n/a · 15% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 83.7% · 1 year 82.8% · 25% evidence · 6 of 6 weeks ahead Exact sum: 28.5 + 19.4 + 9.3 + 12.5 = 69.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 3. [Sun Pharma Advanced Research Company Ltd](https://www.sectoralpha.in/stocks/sun-pharma-advanced-research-company-ltd) SPARC · quiet · Evidence leans up · 78% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 100% · Profit 100% · Operating margin change 455 points · 65% evidence Capital efficiency 16.0/25 · ROCE 164% · Operating margin -85% · 100% evidence Valuation 15.0/20 · P/E 3.6× · PEG n/a · 50% evidence Relative strength 4.3/20 · Lead over its industry -17.4% · Lead over NIFTY 500 9.3% · 1 year 30.9% · 100% evidence · 1 of 12 weeks ahead Exact sum: 25.8 + 16 + 15 + 4.3 = 61.1 · What this means: Earnings are strong; relative strength in its sector is -17.4% and the one-year return is 30.9%. 4. [Remus Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd) REMUS · breaking out · Too little evidence to rank firmly · 54% evidence 54.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 57.3% · Profit 80% · Operating margin change -4 points · 27% evidence Capital efficiency 13.3/25 · ROCE 11.5% · Operating margin 32% · 57% evidence Valuation 11.2/20 · P/E 41.2× · PEG n/a · 50% evidence Relative strength 12.8/20 · Lead over its industry -12.6% · Lead over NIFTY 500 16.6% · 1 year 17.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.5 + 13.3 + 11.2 + 12.8 = 54.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) TTKHLTCARE · quiet · Evidence leans up · 85% evidence 50.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 11.3% · Profit 100% · Operating margin change -1 points · 100% evidence Capital efficiency 6.8/25 · ROCE 8% · Operating margin 1.6% · 100% evidence Valuation 15.7/20 · P/E 17.6× · PEG 1.38 · 100% evidence Relative strength 8.4/20 · Lead over its industry n/a · Lead over NIFTY 500 -3% · 1 year -23.1% · 25% evidence · 10 of 12 weeks ahead Exact sum: 19.8 + 6.8 + 15.7 + 8.4 = 50.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Unichem Laboratories Ltd](https://www.sectoralpha.in/stocks/unichem-laboratories-ltd) UNICHEMLAB · losing its lead · Evidence leans down · 64% evidence 38.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.4/35 · Revenue 7.2% · Profit 100% · Operating margin change 6.7 points · 62% evidence Capital efficiency 6.6/25 · ROCE 4.1% · Operating margin 11% · 76% evidence Valuation 10.0/20 · P/E 27.9× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry -13.3% · Lead over NIFTY 500 15.4% · 1 year 2.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.4 + 6.6 + 10 + 8.3 = 38.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) PANACEABIO · basing · Most evidence points down · 76% evidence 20.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.2/35 · Revenue 10.3% · Profit -80% · Operating margin change 3.5 points · 88% evidence Capital efficiency 1.2/25 · ROCE -2.4% · Operating margin 2.8% · 100% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 1.0/20 · Lead over its industry -38.3% · Lead over NIFTY 500 -16.4% · 1 year -28.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 8.2 + 1.2 + 10 + 1 = 20.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) leader · Too little evidence to rank firmly · 48% evidence 61.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.1/43.75 · Revenue 100% · Profit 100% · Operating margin change 53.1 points · 62% evidence Capital efficiency 19.4/31.25 · ROCE 16.8% · Operating margin 44.7% · 95% evidence Valuation 11.1/25 · P/E 219× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.1 + 19.4 + 11.1 = 61.6 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Jenburkt Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jenburkt-pharmaceuticals-ltd) Too little evidence to rank firmly · 47% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/43.75 · Revenue 11.8% · Profit 6.1% · Operating margin change 6 points · 53% evidence Capital efficiency 21.8/31.25 · ROCE 27.2% · Operating margin 32% · 71% evidence Valuation 14.3/25 · P/E 13.2× · PEG n/a · 50% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.6 + 21.8 + 14.3 = 56.7 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [Madhuveer Com 18 Network Ltd](https://www.sectoralpha.in/stocks/madhuveer-com-18-network-ltd) MADHUVEER · Too little evidence to rank firmly · 33% evidence 42.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.5/43.75 · Revenue 68.7% · Profit 12.8% · Operating margin change 18.4 points · 45% evidence Capital efficiency 11.7/31.25 · ROCE -1.1% · Operating margin 69.7% · 57% evidence Valuation 10.6/25 · P/E 660× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.5 + 11.7 + 10.6 = 42.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Others](https://www.sectoralpha.in/sectors/pharma-others), all 10 compared on one page. ## Which companies are close to Shukra Pharmaceuticals in size? Shukra Pharmaceuticals is the 3rd largest of 10 Pharma - Others companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Sun Pharma Advanced Research Company and Unichem Laboratories. Just below it: Panacea Biotec, Syncom Formulations (India), JOJO and TTK Healthcare. ### Pharma - Others companies close in size

1. [Sun Pharma Advanced Research Company Ltd](https://www.sectoralpha.in/stocks/sun-pharma-advanced-research-company-ltd) ₹5,727 crore
2. [Unichem Laboratories Ltd](https://www.sectoralpha.in/stocks/unichem-laboratories-ltd) ₹3,406 crore
3. Shukra Pharmaceuticals Ltd ₹3,313 crore
4. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) ₹1,919 crore
5. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) ₹1,809 crore
6. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) ₹1,539 crore
7. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) ₹1,279 crore

[All 10 Pharma - Others companies, largest first](https://www.sectoralpha.in/sectors/pharma-others#all-companies)

### Companies close in size in other industries

1. [Network People Services Technologies Ltd](https://www.sectoralpha.in/stocks/network-people-services-technologies-ltd) ₹3,338 crore · IT Product Companies
2. [VST Tillers Tractors Ltd](https://www.sectoralpha.in/stocks/vst-tillers-tractors-ltd) ₹3,330 crore · Auto - Tractors
3. Shukra Pharmaceuticals Ltd ₹3,313 crore
4. [Kirloskar Industries Ltd](https://www.sectoralpha.in/stocks/kirloskar-industries-ltd) ₹3,307 crore · Engines
5. [Heritage Foods Ltd](https://www.sectoralpha.in/stocks/heritage-foods-ltd) ₹3,298 crore · FMCG - Dairy Products

## What else do people ask about Shukra Pharmaceuticals? ### What is Shukra Pharmaceuticals's share price today? Shukra Pharmaceuticals Ltd's share price is ₹79.85, +94.7% over the past year. The whole company is worth ₹3,532 Cr on the market. It is at its highest price of the past 52 weeks (range ₹29 to ₹80), 81.5% above its 200-day average. The price has been rising for 10 weeks (as of 3 November 2026). ### What were Shukra Pharmaceuticals's latest quarterly results? Shukra Pharmaceuticals Ltd reported revenue of ₹24.0 Cr and net profit of ₹15.0 Cr for the Jun 2026 quarter. Revenue rose 380.0% and profit rose 1,400.0% compared with a year earlier. Earnings per share were ₹0.34. The operating margin was 90.0%, 66.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Shukra Pharmaceuticals's market cap? Shukra Pharmaceuticals Ltd's market capitalisation is ₹3,532 Cr at a share price of ₹79.85. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Shukra Pharmaceuticals performing? Shukra Pharmaceuticals Ltd's share price has been rising for 10 weeks. In its latest quarter, revenue rose 380.0% and profit rose 1,400.0% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 14 weeks running (as of 3 November 2026). ### Will Shukra Pharmaceuticals's share price go up? This page does not forecast Shukra Pharmaceuticals Ltd's share price. What it shows instead: the share price is ₹79.85, and it has been rising for 10 weeks. Its P/E of 98.0× is higher than 84% of its own last 11 years (as of 3 November 2026). ### Where is Shukra Pharmaceuticals in its business cycle? Shukra Pharmaceuticals Ltd's FY26 operating margin was 51.0%, against a 13-year range of −10.0% to 51.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 90.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Shukra Pharmaceuticals story? The main question: profits are rising, but only 12% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Shukra Pharmaceuticals a stock worth studying right now? What the numbers show: Shukra Pharmaceuticals Ltd's earnings have grown faster than its share price. Earnings per share grew +127.3% in a year while the price moved +94.7%. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Penny stocks: https://www.sectoralpha.in/penny-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.